{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:50:29Z","timestamp":1778464229092,"version":"3.51.4"},"reference-count":48,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Ann"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>\n            Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by remissions and flares. Twenty percent of SLE presents in childhood where the course of SLE is often more severe with significant morbidity and mortality. Several biologic agents have been developed recently for the treatment of lupus, and although some have proven to be safe and efficacious, many have failed to demonstrate significant benefit in clinical trials. There continues to be a desperate need for safe, effective medications that target specific pathway abnormalities seen in SLE. This is an area of intense research that is changing clinical practice in the treatment of childhood SLE. In this article, we discuss the use of B-cell inhibitors, including belimumab and rituximab, as well as the anti-complement drug eculizumab. Promising treatments on the horizon include the jak-stat inhibitors as well as anifrolumab, which targets interferon.\n            <jats:bold>\n              [\n              <jats:italic>Pediatr Ann<\/jats:italic>\n              . 2022;51(2):e63\u2013e71.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/19382359-20220118-01","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T14:38:39Z","timestamp":1644849519000},"source":"Crossref","is-referenced-by-count":5,"title":["Biologic Agents and Other Emerging Therapies for Childhood SLE"],"prefix":"10.3928","volume":"51","author":[{"given":"Arzu","family":"Soybilgic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38010"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217101"},{"key":"e_1_3_1_5_2","unstructured":"US Food and Drug Administration. Lupus therapies continue to evolve. What will be the focus of treatments to come? Accessed January 27 2022. https:\/\/www.fda.gov\/consumers\/consumer-updates\/lupus-therapies-continue-evolve"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902946419"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2018.17096"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3583-x"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-3"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21664"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315578764"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317751853"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211014267"},{"key":"e_1_3_1_17_2","unstructured":"US Food and Drug Administration. Saphnelo. (anifrolumab-fnia) injection for intravenous use. Accessed January 27 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761123s000lbl.pdf"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216379"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27221"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10856"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab381"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27601"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38260"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.38790"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40479"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000431278"},{"issue":"10","key":"e_1_3_1_28_2","first-page":"S1","article-title":"SM101, a novel recombinant, soluble, human Fc\u03b3IIB receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study","volume":"66","author":"Claudia Kolligs KS","year":"2014","unstructured":"Claudia Kolligs KS. SM101, a novel recombinant, soluble, human Fc\u03b3IIB receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study. Arthritis Rheumatol. 2014;66(10):S1\u2013S1402. https:\/\/onlinelibrary.wiley.com\/toc\/23265205\/2014\/66\/S10","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-017-0225-9"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23361-z"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"e_1_3_1_32_2","unstructured":"US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions. Accessed January 27 2022. https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"e_1_3_1_33_2","unstructured":"US Food and Drug Administration. FDA approves first treatment for pediatric patients with lupus . Accessed January 27 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-pediatric-patients-lupus"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207653"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207654"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab115"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23673"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39856"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206090"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39722"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202460"},{"key":"e_1_3_1_46_2","unstructured":"ImmuPharma. Top line results of LupuzorTM pivotal phase III trial. Accessed January 27 2022. https:\/\/www.immupharma.co.uk\/top-line-results-lupuzor-pivotal-phase-iii-trial\/"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.37940"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01888-5"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41811"}],"container-title":["Pediatric Annals"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:55:32Z","timestamp":1683075332000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/19382359-20220118-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.3928\/19382359-20220118-01"],"URL":"https:\/\/doi.org\/10.3928\/19382359-20220118-01","relation":{},"ISSN":["0090-4481","1938-2359"],"issn-type":[{"value":"0090-4481","type":"print"},{"value":"1938-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}